Rationale: Asthma is associated with complications, cardiovascular comorbidities, and higher mortality in some individuals.
Despite being a relatively benign disease, in some individuals asthma is associated with complications (1), cardiovascular comorbidities (2-7), and high mortality (8) (9) (10) (11) . However, many previous studies have been cross-sectional or retrospective, have not included a representative sample of the general population, and have not adjusted for all relevant confounders. Importantly, many individuals with asthma are also tobacco smokers (12) . Because tobacco smoking is a strong risk factor for pulmonary and cardiovascular diseases, it is difficult to separate the roles of asthma per se and of tobacco smoking regarding prognosis in individuals with asthma (i.e., development of complications, cardiovascular comorbidities, and mortality).
We tested the hypothesis that, in individuals with asthma, never-smokers have different characteristics and a less severe prognosis of the disease than smokers. First, we examined baseline general characteristics, respiratory symptoms, lung function, and levels of inflammatory and allergic biomarkers in the systemic circulation. Second, we assessed prospectively the risk of asthma or chronic obstructive pulmonary disease (COPD) exacerbations; pneumonias; lung cancer; cardiovascular comorbidities, including ischemic heart disease, myocardial infarction, and ischemic stroke; and all-cause mortality.
Methods Study Design and Participants
We recruited 94,079 individuals aged 20-100 years from the Copenhagen General Population Study, a prospective cohort study initiated in 2003 (13, 14) . Participants were randomly selected from the national Danish Civil Registration System to reflect the adult white Danish population of Danish descent. All participants completed a comprehensive questionnaire, underwent a physical examination, and gave blood for biochemical analyses. Questionnaires were reviewed on the day of attendance by an investigator. The response rate was 45%. The study was approved by Herlev Hospital and a Danish ethics committee and was conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants.
Asthma and Smoking
Asthma was defined as an affirmative response to the question: "Do you have asthma"? Smoking status was defined as never, former, or current smokers. Cumulative tobacco consumption was defined as tobacco consumed through smoking and measured in pack-years based on information on the duration of tobacco smoking and current amount of tobacco consumed: 1 pack-year was 20 cigarettes or the equivalent smoked daily for 1 year.
Characteristics
Allergy was defined according to the questionnaire if the participants reported asthma, hay fever, or eczema as a reaction to food, medication, grass, flower, animal hair, or other allergens. Familial predisposition for asthma was as at least one first-degree relative (father, mother, and/or sibling) with asthma. Information on asthma, hay fever, or eczema in childhood was self-reported. Use of asthma medication was defined as taking any kind of medication for asthma and/or bronchitis (including sprays and/or dry powders) daily or almost daily. Wheezing was defined as whistling or wheezing while breathing. Any dyspnea was defined as shortness of breath during different levels of activity, at nighttime, and/or while seated and/or at rest. The modified Medical Research Council dyspnea scale was used to categorize levels of dyspnea according to different levels of activity. Chest pain or tightness was defined as occurring when hurrying or taking the stairs. Sputum was defined as phlegm from the lungs in the morning and/or during the day for as long as 3 consecutive months each year. Cough was defined as exerciseinduced cough.
Spirometry was performed with a spirometer (Vitalograph, Maids Moreton, UK) in the first 14,625 participants and with an EasyOne spirometer (ndd Medical Technologies, Zurich, Switzerland) in the remaining participants. Prebronchodilatatory FEV 1 and FVC were typically measured with at least three sets of values and had two measurements differing by less than 5% as a criterion for reproducibility. The highest measurements of FEV 1 and FVC were used in the analyses. The Vitalograph spirometer was calibrated daily with a 1-L syringe, and the EasyOne spirometer was calibrated regularly as recommended by the manufacturer. FEV 1 , FVC, and FEV 1 /FVC as a percentage of predicted value were calculated using internally derived reference values based on a subsample of healthy, asymptomatic (without wheezing, dyspnea, chest pain or tightness, sputum, cough, and asthma) never-smokers with age and height used as covariates separately for men and women. Predicted values were calculated separately for the two spirometers (see Figure E1 in the online supplement). Individuals with airflow limitation were defined according to (1) a fixed ratio defined as FEV 1 /FVC less than 70% and (2) the lower limit of normal (LLN) defined as FEV 1 /FVC , LLN, and calculated as the mean predicted value for age and sex multiplied by 21.645 standard error. Severity of airflow limitation was assessed using FEV 1 as the percentage of predicted value and categorized into less than 60%, 60-79%, and greater than or equal to 80%. The results were similar when we used the fixed ratio or LLN criterion, so, for simplicity, we report only results derived by using the fixed ratio criterion.
Biomarkers in the systemic circulation of inflammation, such as C-reactive protein, fibrinogen, whole blood leukocyte count, and whole blood neutrophils, and of allergy-like whole blood eosinophils and immunoglobulin E were measured using standard hospital assays; measurement of immunoglobulin E was available only in a subgroup of 38,962 participants.
At a Glance Commentary
Scientific Knowledge on the Subject: Asthma is associated with complications, cardiovascular comorbidities, and higher mortality in some individuals. However, many individuals with asthma are also tobacco smokers. Because tobacco smoking is a strong risk factor for pulmonary and cardiovascular diseases, it is difficult to separate the roles of asthma per se and of tobacco smoking regarding prognosis in individuals with asthma.
What This Study Adds to the
Field: Never-smokers with asthma experience an increased risk of asthma and chronic obstructive pulmonary disease exacerbations, and possibly pneumonias. Importantly, risks of lung cancer, cardiovascular comorbidities, and death were restricted to smokers with asthma. Thus, this study substantiates that tobacco smoking is the main explanation of poor prognosis in some individuals with asthma. All individuals in Denmark are assigned a unique identification number at birth or immigration through the national Danish Civil Registration System, by which they can be tracked in the registries described above. Thus, not a single person was lost to follow-up, and the individuals who emigrated were censored at the date of emigration. Also, the national Danish Patient Registry and Danish Cancer Registry have high validity of recorded data (15, 16) .
Covariates
Systolic and diastolic blood pressures were measured using automated equipment. Plasma levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were measured using standard hospital assays.
Diabetes at baseline was (1) self-reported diabetes, (2) 2 ). Information on use of cholesterol-lowering medication, leisure time physical activity, education, annual household income, alcohol consumption, occupational exposure to dust and/or fumes, and daily exposure to passive smoking was derived from the questionnaire.
Statistical Analyses
We used the Wilcoxon nonparametric ranksum test for continuous data, the Pearson x 2 test for categorical data, and the Cuzick nonparametric test for trend across ordered groups. Associations of age with FEV 1 and FVC as a percentage of predicted value and with FEV 1 /FVC were examined using multiple linear regressions. Inflammatory and allergic biomarkers in the systemic circulation were log-normally distributed; thus, differences were assessed using log-transformed values and depicted using geometric means with age and sex as covariates. Multivariable adjusted Cox proportional hazard ratios with 95% confidence intervals were used in the prospective analyses to determine risk of asthma or COPD exacerbations, pneumonias, lung cancer, cardiovascular comorbidities, and all-cause mortality, with never-smokers without asthma used as the reference group. For exacerbations and pneumonias, we performed multiple failure time analysis using the Andersen-Gill approach (17) ; otherwise, an approach with single failure time analysis was used. The Wald test was used to assess for interactions. Because the results of previous studies indicate that asthma may be a risk factor for cardiovascular comorbidities only in women (2, 5, 6) , the interaction of sex and asthma on risk of cardiovascular comorbidities was investigated. Additionally, as disease incidences change with aging (18), interaction of age and asthma on all endpoints was investigated. Finally, interaction of tobacco smoking and asthma on all endpoints was investigated to assess the effect modification of asthma. Models of risk of asthma or COPD exacerbations, pneumonias, and lung cancer were adjusted for potential confounders associated with one or more of these diseases (i.e., for age; sex; BMI; allergy; familial predisposition for asthma; childhood asthma, hay fever, or eczema; use of asthma medication; occupational exposure to dust and/or fumes; daily exposure to passive smoking; leisure time physical activity; education; annual household income; and cumulative tobacco consumption). Models of risk of cardiovascular comorbidities were adjusted for potential confounders associated with one or more of these diseases (i.e., for age, sex, BMI, leisure time physical activity, education, annual household income, alcohol consumption, cumulative tobacco consumption, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, use of cholesterol-lowering medication, and presence of diabetes). The model of risk of all-cause mortality was adjusted for all of the above-mentioned covariates, as all of them may be relevant with regard to this endpoint. Kaplan-Meier curves and a log-rank test were used to compare cumulative survival. When we compared models including other covariates for tobacco consumption (duration of tobacco smoking and daily amount of consumed tobacco) compared with using cumulative tobacco consumption as pack-years only, the models showed no improvement.
Covariates used for adjustment in the prospective analyses were 99.2% complete. Therefore, we performed multivariate imputation using chained equations to fill out the missing values; however, the results were similar without the use of imputation.
All statistical analyses were performed using STATA/SE 13.0 for Windows (StataCorp, College Station, TX).
Results
Among 94,079 participants in the general population, 5,691 (6%) reported having asthma, including 2,304 never-smokers, 2,467 former smokers, and 920 current smokers ( Figure E2 ).
Characteristics
Compared with never-smokers without asthma, individuals with asthma had a higher prevalence of respiratory symptoms and airflow limitation, which was most pronounced among smokers (Table 1) . Similar trends could be observed among individuals without asthma; however, individuals with asthma consistently had a higher prevalence of respiratory symptoms and airflow limitation (Table  E1 ). Among individuals with asthma, 23% of never-smokers, 38% of former smokers, and 47% of current smokers had airflow limitation. Additionally, the differences with regard to FEV 1 percentage of predicted value, FVC percentage of predicted value, and FEV 1 /FVC between never-smokers with or without asthma increased with increasing age (Figure 1 and Figure E3 with 95% confidence intervals in the online supplement). Furthermore, these differences from never through former to current smokers with asthma likewise differed increasingly with increasing age.
Levels of biomarkers of inflammation and allergy in the systemic circulation were higher in never-smokers with asthma compared with never-smokers without asthma ( Figure 2 and Table E2 ). Among individuals with asthma, former and current smokers versus never-smokers had higher levels of inflammatory biomarkers, including C-reactive protein, fibrinogen, whole blood leukocyte count, and whole blood neutrophils; however, no differences were observed in levels of allergic biomarkers, including whole blood eosinophils and immunoglobulin E. Additionally, levels of allergic biomarkers were higher among individuals with allergy compared with individuals without allergy, especially among individuals with asthma (Table E3) .
Complications
During a mean follow-up of 4.5 years, we observed 204 asthma exacerbations, 614 COPD exacerbations, 1,279 pneumonias, and 62 cases of lung cancer (Figure 3 ). Among individuals with asthma and compared with never-smokers without asthma, multivariable adjusted hazard ratios for asthma exacerbations were 11 (95% confidence interval: 5. 
Cardiovascular Comorbidities
During a mean follow-up of 4.5 years, we observed 1,027 ischemic heart disease events, 347 myocardial infarctions, and 399 ischemic strokes (Figure 3 ). Among individuals with asthma and compared with never-smokers without asthma, multivariable adjusted hazard ratios for ischemic heart disease were 1.2 (0.9-1.6) in never-smokers, 1.5 (1.2-2.0) in former smokers, and 2.0 (1.4-2.9) in current smokers. The respective corresponding values were 1.3 (0.8-2.0), 1.7 (1.1-2.6), and 3.2 (1.8-5.8) for myocardial infarction and 1.4 (0.9-2.1), 1.2 (0.8-1.9), and 3.0 (1.7-5.3) for ischemic stroke. Although risk estimates were nominally higher among women, the interaction analyses did not suggest differences in risk of cardiovascular comorbidities between men and women ( Figure E4 ).
Mortality
During a mean follow-up of 4.5 years, 1,191 participants died (Figures 3 and 4) . Among individuals with asthma and compared with never-smokers without asthma, multivariable adjusted hazard ratios for all-cause mortality were 0.9 (0.6-1.3) in never-smokers, 1.5 (1.1-2.0) in former smokers, and 2.7 (1.9-3.7) in current smokers.
Sensitivity Analyses
The risk of complications was also investigated without including potential confounders that could be associated with asthma; however, the findings were similar (compare Figure 3 with Figure E5 ). Additionally, dividing individuals with asthma according to cumulative tobacco consumption instead of by smoking status gave similar results (compare Figure 3 with Figure E6 ). Interaction analyses did not suggest differences between younger and older individuals ( Figure E7 ). Although individuals with asthma compared with individuals without asthma had a higher risk of complications and cardiovascular comorbidities, there was no evidence of statistical interaction ( Figure E8 ). By contrast, former and current smokers with asthma possibly were at increased risk of all-cause mortality compared with former and current smokers without asthma, suggesting a higher vulnerability to smoking in asthma ( Figure E8 ), but the P value for interaction was only borderline significant (P = 0.04).
Discussion
We found that, in the general population, tobacco smoking strongly influenced the clinical presentation and prognosis of asthma. As expected, never-smokers with asthma presented with more respiratory symptoms and airflow limitation and had an increased risk of asthma and COPD exacerbations, and possibly of pneumonias, compared with never-smokers without asthma. However, these attributes were even more pronounced in former and current smokers with asthma. Importantly, the risks of lung cancer, cardiovascular comorbidities, and death were restricted to former and current smokers with asthma. Thus, tobacco smoking appears to be the explanation of poor prognosis, especially with regard to lung cancer, cardiovascular diseases, and mortality, in individuals with asthma in the general population, and not asthma per se. These findings have important public implications because the prevalence of tobacco smoking is high in individuals with asthma (12) .
It is a general perception that the disease process is mainly limited to the lungs in asthma as opposed to COPD, which has a substantial systemic component (19) . Although we found elevated levels of inflammatory biomarkers in the systemic circulation, including in never-smokers with asthma, the relative increase was lower than in COPD (13). Thus, airway inflammation in asthma may lead to increased susceptibility to local disease (i.e., exacerbations and possibly pneumonias), but not to extrapulmonary comorbidities (i.e., systemic disease). Because asthma is an established risk factor for irreversible airflow limitation (20) (21) (22) , it is not surprising that we also observed an increased risk of COPD exacerbations among individuals with asthma independent of tobacco smoking. Indeed, recently it has been demonstrated Definition of abbreviations: BMI = body mass index; LLN = lower limit of normal; mMRC = modified Medical Research Council dyspnea scale. Data are summarized as median with the 25th and 75th percentiles or as percentage. *P value for trend in asthma calculated using the Cuzick nonparametric trend test across ordered groups (never-smokers through former smokers to current smokers). † P , 0.05 for comparison between never-smokers without asthma and never-smokers with asthma, calculated using the Wilcoxon nonparametric rank-sum test if comparing continuous data and the Pearson x 2 test if comparing categorical data. ‡ P , 0.001 for comparison between never-smokers without asthma and never-smokers with asthma, calculated using the Wilcoxon nonparametric rank-sum test if comparing continuous data and the Pearson x 2 test test if comparing categorical data. x P , 0.001 for comparison between former and current smokers with asthma calculated using the Wilcoxon nonparametric rank-sum test.
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Any dyspnea was defined as shortness of breath during different levels of activity, at nighttime, and/or while seated and/or at rest. that the risk of airflow limitation is increased 10-to 20-fold among individuals with asthma compared with those without it, regardless of smoking status, especially in early-onset asthma (23) . The higher risk estimates for exacerbations and pneumonias in former and current smokers versus never-smokers with asthma may also be explained by the fact that inhaled corticosteroids work less well in individuals with asthma who smoke (24, 25) .
We suggest that lung cancer and cardiovascular comorbidities in asthma arise mainly from tobacco smoking. Supportive of this notion is that we recently found in another study that never-smokers without asthma but with airflow limitation compatible with COPD likewise were not at risk of lung cancer or cardiovascular comorbidities compared with never-smokers without COPD (13) . Another possible explanation could be that tobacco smokers with asthma or COPD have more severe airflow limitation, as impaired lung function has been shown to be inversely related to increased mortality due to cardiovascular comorbidities independent of tobacco smoking, but not to lung cancer (26, 27) .
Previous findings suggest that asthma is associated with increased risk of cardiovascular comorbidities (2-7). However, some of these findings were limited to women (2, 5, 6) or could not be reproduced in never-smokers with asthma (6) . Furthermore, most of these studies were cross-sectional or retrospective and did not include a representative sample of the general population. In addition, the researchers in these studies did not adjust for all relevant confounders, especially regarding cardiovascular risk factors. Thus, confounding may be a plausible explanation for some previous findings. Taken together with the present findings, the sum of evidence therefore seems to suggest that asthma per se is not a cause of cardiovascular comorbidities, which in individuals with asthma seem to be restricted to smokers.
The authors of a recent metaanalysis concluded that there is a lack of evidence to support asthma as an independent risk factor for lung cancer and suggested that such an association may be a result of residual confounding and/or reverse Figure 1 . Lung function by age according to presence of asthma and smoking status. Models were multivariable adjusted for age; body mass index; familial predisposition for asthma; allergy; childhood asthma, hay fever, or eczema; use of asthma medication; occupational exposure to dust and/or fumes; daily exposure to passive smoking; leisure time physical activity; education; annual household income; and cumulative tobacco consumption. The model of the FEV 1 /FVC ratio was additionally adjusted for sex and height. Models are based on cross-sectional measurements of lung function obtained at the examination. P value for trend in asthma was restricted to those with asthma.
causation (28) . Thus, that metaanalysis, together with the present findings, seem to support that asthma per se is not a cause of lung cancer, which in individuals with asthma is restricted to smokers. We previously found an increased risk of death in individuals with asthma, including never-smokers, in the Copenhagen City Heart Study (9) . This finding has been reported in other populations as well (8, 10, 11) . However, since treatment and management of asthma has improved during recent decades, mortality may have declined in individuals with asthma and it is reassuring that we observed similar mortality in never-smokers with and without asthma. Yet, as tobacco smoking is associated with increased exacerbations, decline in lung function, and risk of developing irreversible airflow limitation (20, 29) , former and current smokers with asthma still have an increased risk of death, as demonstrated in our study. Supported by the present findings, smoking cessation needs to be an important strategy in the management of asthma. Indeed, the prevalence of tobacco smoking is high even in individuals with asthma, and it is estimated to be up to one-third (30) (31) (32) (33) . In the present study, the prevalence of current smokers was 16%, corresponding well to what has been observed in other countries in Western Europe (30) . Furthermore, the prevalence of current smokers was close to the general population (18%), also corresponding well with previous observations (30) (31) (32) (33) .
Strengths of the present study include the use of a large sample from the general population with a large number of individuals with asthma and the fact that we did not lose track of even a single person during follow-up. We also had information on several potential confounders, especially related to development of cardiovascular disease, and detailed information on smoking.
A limitation of the present study includes the diagnosis of asthma, which was self-reported and not defined according to the presence of reversible or variable airflow limitation and/or airway hyperresponsiveness (34) . However, selfreported asthma has been evaluated rigorously before and displays high specificity and sensitivity (35) compared with airway hyperresponsiveness, which displays only high specificity and low sensitivity (36) . Also, levels of whole blood eosinophils and immunoglobulin E were higher among individuals with asthma, including in never-smokers, which suggests that individuals with asthma were indeed identified in the population. Nevertheless, lack of information about presence of physiciandiagnosed asthma in the questionnaire prevented us from investigating the reliability of the self-reported diagnosis of asthma.
Another limitation is lack of postbronchodilator spirometric values. Thus, some individuals with asthma may have COPD and/or asthma-COPD overlap syndrome instead (34) . However, tobacco smoking remains the single most important risk factor for COPD; thus, it is not completely unreasonable to assume that findings in never-smokers with asthma were not affected by the lack of post-bronchodilator spirometric values. Nevertheless, there is a real risk of misclassification with regard to former and current smokers. However, sensitivity analyses did not indicate this to be a major problem, as the risk of lung cancer should be higher among individuals with COPD who had smoked, Hazard ratio (95% Cl) 40 Figure 3 . Risk of complications, cardiovascular comorbidities, and mortality according to presence of asthma and smoking status. Models of exacerbations of asthma and chronic obstructive pulmonary disease (COPD), pneumonias, and lung cancer were multivariable adjusted for age; sex; body mass index; familial predisposition for asthma; allergy; childhood asthma, hay fever, or eczema; use of asthma medication; occupational exposure to dust and/or fumes; daily exposure to passive smoking; leisure time physical activity; education; annual household income; and cumulative tobacco consumption. Models of cardiovascular comorbidities were multivariable adjusted for age, sex, body mass index, leisure time physical activity, education, annual household income, alcohol consumption, cumulative tobacco consumption, systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, use of cholesterol-lowering medication, and presence of diabetes. Models of risk of all-cause mortality were multivariable adjusted for all of the above-mentioned covariates. The numbers of individuals for cardiovascular comorbidities differ slightly because of exclusion of participants with the outcome at baseline. The number of individuals for lung cancer differs slightly because of availability of data. CI = confidence interval; HR = hazard ratio.
but that was not observed for individuals with asthma. Finally, we cannot exclude the possibility of a nonresponse bias, as the response rate was 45%. It is not uncommon that individuals who are severely ill and chronically disabled are incapable of participating in epidemiological surveys, which may in the worst case lead to an underestimate of the poor prognosis of asthma.
Never-smokers with asthma experience an increased risk of asthma and COPD exacerbations, and possibly of pneumonias. Importantly, risks of lung cancer, cardiovascular comorbidities, and death were restricted to smokers with asthma. Thus, this study substantiates that tobacco smoking is the main explanation of poor prognosis in some individuals with asthma. n log-rank in never-smokers with asthma versus never-smokers without asthma: P = 0.49 Figure 4 . Kaplan-Meier survival curves according to presence of asthma and smoking status. Because age is used as a timescale and individuals entered the study at different ages, the numbers of individuals at risk in each age group are lower than the total numbers given in Table 1 ; however, all individuals in Table 1 were entered into this analysis.
